Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg raises target price on Johnson Matthey

(Sharecast News) - Analysts at Berenberg raised their target price on chemicals and sustainable technologies company Johnson Matthey from 1,800.0p to 1,950.0p on Tuesday, noting that the stock's 40% year-to-date share-price performance has been "one of the few pleasant surprises" for chemicals investors in 2025. Bernberg said a "well-received divestment" of Johnson Matthey's catalysts technologies segment, improvement in FY25 margins for clean air and higher platinum group metal prices all played a role in the stock's outperformance.

As a rough estimate, Berenberg believes that around half of Johnson Matthey's share price outperformance can be attributed to the divestment, 35% to PGM prices and 15% to higher margins in clean air.

The German bank also said higher, more volatile PGM prices mean consensus underlying earnings estimates for Johnson Matthey were "a mid-single-digit percentage too low for the next few years".

"Yet the shares have run hard and additional PGM capacity will come to the market with the Platreef project in 2026," said Berenberg, which retained its 'hold' rating on the stock.

"The mid-single-digit percentage increases to our EPS estimates for FY26-27 reflect the tailwind to the PGM Services segment from higher PGM prices and volatility. The shares trade on FY27E EV/EBITDA of c6x and FCF yield of just over 10%, which we think is fair for a cash-focused ex-growth asset."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.